Nadine McGrath
Journalist at Stockhead
Journalist specialising in finance & economy working @stockheadAU. Views expressed here are my own.
Articles
-
5 days ago |
stockhead.com.au | Nadine McGrath
DTR made a date with the moon in May.
-
1 week ago |
stockhead.com.au | Nadine McGrath
ASX health stocks up 1.2% over past five days while the broader market is up 0.8% HealthCo REIT agrees to short-term partial rent deferral with troubled Healthscope and its receiversNew-Zealand-based soft-tissue repair company Aroa Biosurgery delivers maiden full-year profitHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his ‘Powerplay’ stock pick.
-
1 week ago |
stockhead.com.au | Nadine McGrath
Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnest. In brief, this is what the markets have been up to this morning.
-
2 weeks ago |
stockhead.com.au | Nadine McGrath
ASX health stocks up 0.57% over past week, while the broader market is up 0.35% Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheetsMonash IVF’s woes continue with company downgrading FY25 blaming softer marketHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his ‘Powerplay’ stock pick.
-
2 weeks ago |
stockhead.com.au | Nadine McGrath
Australia has become well-known for its paediatric drug discovery with several life-altering treatmentsCSL is a global leader in developing therapies for children with haemophilia and other serious blood disordersNeurotech International is at forefront of developing cannabinoid-derived therapies for paediatric neurological disordersAustralia may lack the size and funding of larger global biotech hubs, but it consistently punches above its weight in paediatric drug discovery.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 524
- Tweets
- 571
- DMs Open
- No
Clinical trials have become big business in Australia. So what are some of the #ASX health stocks undertaking trials at home?
Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022, according to @MTPConnect_AUS . Nadine McGrath looks into some of the #ASX companies undertaking trials in Australia.https://t.co/GY7rbSYznG https://t.co/z7ycwQqUnd
I've been delving into the latest report of Australia's clinical trial sector by @MTPConnect_AUS showing it has become a valuable part of the Australian economy. So just what makes Australia a 'go-to' destination for clinical trials?
Australia has established established a global reputation as a ‘go to’ destination to conduct clinical trials according to @MTPConnect_AUS with @ArgenicaT and @NeurotechInt among #ASX companies undertaking clinical trials locally. https://t.co/DvUJH2F6jW https://t.co/aeBfETqgAc
Australia has some of the best up-and-coming health and biotech companies but where to start if you're an investor. Checkout our Stockhead special investor guide. #ASX #biotech
In this special investor guide, #health and #biotech guru Tim Boreham leads Stockhead’s deep dive into the most cutting edge sector on the #ASX. https://t.co/Cb12HOZBKZ
